Michael Y. Mapa

Array ( [id] => 18003490 [patent_doc_number] => 20220362256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => DISRUPTION OF VASCULAR SMOOTH MUSCLE RELAXATION BY CARFILZOMIB MAY BE THE PRIMARY REASON FOR CFZ-INDUCED VASCULAR DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/771152 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19113188 [patent_doc_number] => 20240124938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS [patent_app_type] => utility [patent_app_number] => 17/768642 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125662 [patent_doc_number] => 20240131015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => MEDICAMENT FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF CANCERS [patent_app_type] => utility [patent_app_number] => 17/769502 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345059 [patent_doc_number] => 20230133169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/768807 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125662 [patent_doc_number] => 20240131015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => MEDICAMENT FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF CANCERS [patent_app_type] => utility [patent_app_number] => 17/769502 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18055525 [patent_doc_number] => 20220386611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES [patent_app_type] => utility [patent_app_number] => 17/762779 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18195712 [patent_doc_number] => 20230049231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS [patent_app_type] => utility [patent_app_number] => 17/766834 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 385 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056263 [patent_doc_number] => 20220387349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => TREATMENT OF CUTANEOUS ADVERSE EFFECTS CAUSED BY ONCOLOGICAL THERAPY WITH TOPICAL TAPINAROF COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/763231 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20534512 [patent_doc_number] => 12551563 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => ERK5 degraders as therapeutics in cancer and inflammatory diseases [patent_app_type] => utility [patent_app_number] => 17/761096 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15572 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146806 [patent_doc_number] => 20230020663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/760886 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18280631 [patent_doc_number] => 20230096103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/759480 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527240 [patent_doc_number] => 12545664 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Composition of matter for use in organic light-emitting diodes [patent_app_type] => utility [patent_app_number] => 17/639749 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12872 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036118 [patent_doc_number] => 20220380333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => CANNABINOID DERIVATIVES, PRECURSORS AND USES [patent_app_type] => utility [patent_app_number] => 17/753616 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881057 [patent_doc_number] => 20220296534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => SCYLLO-INOSITOL AND B-CELL MEDIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/753316 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17866971 [patent_doc_number] => 20220289706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID DERIVATIVES OF3-BROM0-4,5-DIHYDRO-1H-PYRAZOLES [patent_app_type] => utility [patent_app_number] => 17/636712 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851801 [patent_doc_number] => 20220281843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => KIF18A INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/632338 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776480 [patent_doc_number] => 20220242829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => PROCESS FOR PREPARATION OF ENZALUTAMIDE [patent_app_type] => utility [patent_app_number] => 17/620314 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20240928 [patent_doc_number] => 12421236 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor [patent_app_type] => utility [patent_app_number] => 17/621621 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4210 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17829985 [patent_doc_number] => 20220267289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => SELECTIVE BCRP/ABCG2 TRANSPORTER INHIBITORS AS AGENTS TO ABOLISH RESISTANCE TO ANTI-CANCER AGENTS [patent_app_type] => utility [patent_app_number] => 17/629966 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851793 [patent_doc_number] => 20220281835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE [patent_app_type] => utility [patent_app_number] => 17/627996 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627996 [rel_patent_id] =>[rel_patent_doc_number] =>)